硫酸镁联合拉贝洛尔与单用硫酸镁治疗妊娠期高血压疾病的临床效果

打开文本图片集

【摘要】目的：探讨硫酸镁联合拉贝洛尔与单用硫酸镁治疗妊娠期高血压疾病（HDP）的临床效果。方法：选择2021年1月—2023年12月医院40例HDP患者，随机分为两组，观察组采用硫酸镁联合拉贝洛尔治疗，对照组单用硫酸镁治疗，比较两组血压、血液流变学、炎症因子、妊娠结局。结果：观察组治疗2周舒张压、收缩压低于对照组，红细胞比容（HCT）与血浆黏度低于对照组，肿瘤坏死因子α（TNF-α）、白细胞介素6（IL-6）低于对照组，观察组不良妊娠结局发生率低于对照组，差异有统计学意义（P

【关键词】妊娠期高血压疾病；硫酸镁；拉贝洛尔；血压；血液流变学；炎症因子；妊娠结局

Clinical effect of magnesium sulfate combined with labetalol and magnesium sulfate alone in the treatment of hypertensive diseases during pregnancy

SONG Zhaoxia

Department of Obstetrics， Huaiyin Maternal and Child Health Hospital， Huaian City， Jiangsu Province， Huaian， Jiangsu 223300， China

【Abstract】Objective： To explore the clinical effect of magnesium sulfate combined with rabelol and magnesium sulfate alone in the treatment of gestational hypertension. Methods： Forty patients with gestational hypertension were randomly divided into two groups from January 2021 to December 2023. The observation group was treated with magnesium sulfate combined with rabolol， while the control group was treated with magnesium sulfate alone. Blood pressure， hemorheology， inflammatory factors， and pregnancy outcomes were compared between the two groups. Results： The observation group had lower diastolic and systolic blood pressure， lower hematocrit （HCT） and plasma viscosity， and tumor necrosis factor compared to the control group after 2 weeks of treatment α （TNF-α）、The level of interleukin-6 （IL-6） was lower in the observation group than in the control group， and the incidence of adverse pregnancy outcomes was lower in the observation group， with a statistically significant difference （P

【Key Words】Pregnancy induced hypertension； Magnesium sulfate； Rabelol； Blood pressure； Hemorheology； Inflammatory factors； Pregnancy outcome

妊娠期高血壓疾病（HDP）是妊娠与血压升高并存的一组疾病，通常在妊娠20周后出现，病情可持续性进展，伴随着蛋白尿和肾功能异常[1]。（剩余3933字）